The remarks from Peter Marks, director of the Center for Biologics Evaluation and Research, came during a webinar as the FDA prepares to meet Oct. 14 and 15 with its outside advisers to discuss boosters for the Moderna and Johnson & Johnson vaccines.

J&J on Tuesday asked the FDA to grant emergency use authorization for a booster dose of its one-shot coronavirus vaccine, making it the third company to ask the Biden administration to approve additional doses.

Here’s what to know

• President Biden’s planned vaccine requirement faces a number of tests in the coming weeks, as at least two dozen Republican-controlled states prepare legal challenges, setting up a clash between the federal government and local officials that could ultimately determine the fate of the rule.
• Facebook whistleblower Frances Haugen told lawmakers that she believes Facebook is ill-equipped to quash the spread of medical misinformation on its platforms, an issue that has drawn scrutiny from Democrats on Capitol Hill.
• The ferocity of the delta variant surge has delivered a serious financial blow to hospital systems in parts of the country with low vaccination rates that are struggling to care for coronavirus patients.
• In August, for the first time in the pandemic, the rate of coronavirus infections among children topped those for adults ages 18 to 64 and seniors, driven by the highly contagious delta variant, according to a Washington Post analysis of Centers for Disease Control and Prevention data.
• The European Union’s top drug regulator recommended additional vaccine doses for people over 18 and the immunocompromised.
• National Institutes of Health Director Francis S. Collins, one of the most recognizable leaders in the coronavirus pandemic, will leave his post by the end of this year, NIH announced Tuesday.